News & Updates

Show Multimedia Only

Dupilumab shows therapeutic potential in eosinophilic gastritis

15 Jul 2026

In the treatment of patients with eosinophilic gastritis, the use of dupilumab helps improve histological outcomes, according to the proof-of-concept, phase II DEGAS study.

Dupilumab shows therapeutic potential in eosinophilic gastritis

15 Jul 2026

Patients with MASLD face heightened diabetes risk

14 Jul 2026 by

Metabolic dysfunction-associated steatotic liver disease (MASLD) carries an increased risk of type 2 diabetes (T2D), with the risk increase disproportionately higher for individuals with earlier-onset MASLD, as shown in a study.

Patients with MASLD face heightened diabetes risk

14 Jul 2026

Long-term dupilumab sustains symptom improvement in paediatric EoE

13 Jul 2026 by

Treatment with dupilumab for up to 100 weeks reduces the frequency and severity of symptoms in children with eosinophilic esophagitis (EoE), as measured by the validated Pediatric Eosinophilic Esophagitis Symptom Score version 2.0 (PEESSv2.0), according to results from the open-label extension of the phase III EoE KIDS study.

Long-term dupilumab sustains symptom improvement in paediatric EoE

13 Jul 2026

Ustekinumab Q4W dosing induces response, remission in children with moderate-to-severe UC

12 Jul 2026 by

Paediatric patients with moderately to severely active ulcerative colitis (UC) show a favourable response to ustekinumab administered once every 4 weeks (Q4W), according to a study. This results in greater clinical response and remission associated with higher serum drug levels.

Ustekinumab Q4W dosing induces response, remission in children with moderate-to-severe UC

12 Jul 2026

Link between protein type, mortality differs by sex, adiposity

10 Jul 2026

Sex, smoking status, and adiposity mediate the associations between dietary animal (AP) and plant proteins (PP) and mortality, reports a study.

Link between protein type, mortality differs by sex, adiposity

10 Jul 2026

Original New Drug Application Approvals by US FDA (16-30 June 2026)

09 Jul 2026

New drug applications approved by US FDA as of 16-30 June 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 June 2026)

09 Jul 2026

Hepatic steatosis increases non-calcified plaque burden

08 Jul 2026

Hepatic steatosis may raise the risk of major adverse cardiovascular events through increased non-calcified plaque burden, according to a study.

Hepatic steatosis increases non-calcified plaque burden

08 Jul 2026

Dysphagia a red flag for poor outcomes after cardiovascular procedures

08 Jul 2026 by

Among individuals undergoing common cardiovascular procedures, those with a preoperative diagnosis of dysphagia face an increased risk of postoperative mortality and complications, according to a retrospective study.

Dysphagia a red flag for poor outcomes after cardiovascular procedures

08 Jul 2026

Camrelizumab plus apatinib shows promising safety, efficacy in ESCC

08 Jul 2026

Treatment with camrelizumab combined with apatinib demonstrates improvements in overall survival (OS), progression-free survival (PFS), and response rates in patients with esophageal squamous cell carcinoma (ESCC), a study has shown.

Camrelizumab plus apatinib shows promising safety, efficacy in ESCC

08 Jul 2026

No clear link between prenatal acid suppressant use and IBD in offspring

07 Jul 2026

In vitro exposure to acid-suppressive medications does not appear to be associated with an increased risk of inflammatory bowel disease (IBD) development in offspring, as shown in a nationwide cohort study.

No clear link between prenatal acid suppressant use and IBD in offspring

07 Jul 2026

News & Updates

Showing Gastroenterology articles

Showing

Specialty:

Dupilumab shows therapeutic potential in eosinophilic gastritis

Dupilumab shows therapeutic potential in eosinophilic gastritis

Patients with MASLD face heightened diabetes risk

Patients with MASLD face heightened diabetes risk

Long-term dupilumab sustains symptom improvement in paediatric EoE

Long-term dupilumab sustains symptom improvement in paediatric EoE

Ustekinumab Q4W dosing induces response, remission in children with moderate-to-severe UC

Ustekinumab Q4W dosing induces response, remission in children with moderate-to-severe UC

Link between protein type, mortality differs by sex, adiposity

Link between protein type, mortality differs by sex, adiposity

Original New Drug Application Approvals by US FDA (16-30 June 2026)

Original New Drug Application Approvals by US FDA (16-30 June 2026)

Hepatic steatosis increases non-calcified plaque burden

Hepatic steatosis increases non-calcified plaque burden

Dysphagia a red flag for poor outcomes after cardiovascular procedures

Dysphagia a red flag for poor outcomes after cardiovascular procedures

Camrelizumab plus apatinib shows promising safety, efficacy in ESCC

Camrelizumab plus apatinib shows promising safety, efficacy in ESCC

No clear link between prenatal acid suppressant use and IBD in offspring

No clear link between prenatal acid suppressant use and IBD in offspring